Page 102 - BPOM Terbitkan EUA Vaksin Indovac dan Vaksin AWcorna
P. 102

Judul              :  IndoVac Be the First Vaccine COVID-19 Made in Indonesia
               Nama Media         :  viva.co.id
               Tanggal            :  9/30/2022
               Halaman/URL        :  https://www.viva.co.id/english/1527322-indovac-be-the-first-vaccine-
                                     covid-19-made-in-indonesia
               Tipe Media         :  Media Online

                                                                       Head  of  the  Food  and  Drug
                                                                       Supervisory Agency (BPOM), Penny
                                                                       K  Lukito  said  Merah  Putih  Vaccine
                                                                       with  the  trademark  IndoVac  is  the
                                                                       first   COVID-19     vaccine    that
                                                                       producing  in  Indonesia  through  PT
                                                                       Bio  Farma's  production  facility  in
                                                                       Bandung, West Java.

                                                                       During  a  press  conference  for  the
                                                                       issuance  of  an  Emergency  Use
                                                                       Permit (EUA) for Domestic COVID-
                                                                       19  Vaccines  at  the  BPOM  RI
                                                                       Building,   Jakarta,   on    Friday,
               September  30,  2022,  Penny  K  Lukito  said  the  IndoVac  Vaccine  was  the  first  COVID-19
               vaccine to be produced locally in the country.

               BPOM issued an Emergency Use Authorization (EUA) for the IndoVac Vaccine on September
               24, 2022.

               The emergency use permit is the initial door of access to obtain the COVID-19 vaccine that
               the community needs as a strategic effort in dealing with the pandemic and protecting against
               COVID-19.

               Penny  K  Lukito  conveyed  that  IndoVac  is  a  COVID-19  vaccine  containing  the  active
               substance recombinant Receptor-Binding Domain (RBD) protein S of the SARS-Cov-2 virus
               with a recombinant protein subunit platform developed by PT Bio Farma in collaboration with
               Baylor College of Medicine, USA.

               By EUA requirements, BPOM has previously evaluated the aspects of the efficacy, safety, and
               quality  of  the  IndoVac  Vaccine  by  referring  to  the  internationally  applicable  COVID-19
               vaccine  evaluation  standards,  as  well  as  evaluating  the  fulfillment  of  Good  Manufacturing
   97   98   99   100   101   102   103   104   105   106   107